Francois Dreyfus
Overview
Explore the profile of Francois Dreyfus including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
87
Citations
4612
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Park S, Kosmider O, Maloisel F, Drenou B, Chapuis N, Lefebvre T, et al.
Haematologica
. 2018 Oct;
104(3):497-504.
PMID: 30287621
Erythropoiesis-stimulating agents are generally the first line of treatment of anemia in patients with lower-risk myelodysplastic syndrome. We prospectively investigated the predictive value of somatic mutations, and biomarkers of ineffective...
2.
Miyazaki Y, Tuechler H, Sanz G, Schanz J, Garcia-Manero G, Sole F, et al.
Leuk Res
. 2018 Sep;
73:51-57.
PMID: 30219650
Clinical features of myelodysplastic syndromes (MDS) could be influenced by many factors, such as disease intrinsic factors (e.g., morphologic, cytogenetic, molecular), extrinsic factors (e.g, management, environment), and ethnicity. Several previous...
3.
Rose C, Lenoir C, Gyan E, Hacini M, Ame S, Corront B, et al.
Eur J Haematol
. 2018 May;
PMID: 29719933
Objectives: To assess the reduction of transfusions rate in transfusion-dependent patients with low-risk myelodysplastic syndrome (MDS) with iron overload treated with deferasirox. Methods: Prospective observational study. Primary endpoint was reduction...
4.
Park S, Kelaidi C, Dreyfus F
Oncotarget
. 2017 Nov;
8(45):78255-78256.
PMID: 29108222
No abstract available.
5.
Park S, Hamel J, Toma A, Kelaidi C, Thepot S, Diez Campelo M, et al.
J Clin Oncol
. 2017 Mar;
35(14):1591-1597.
PMID: 28350519
Purpose Most anemic patients with non-deleted 5q lower-risk myelodysplastic syndromes (MDS) are treated with erythropoiesis-stimulating agents (ESAs), with a response rate of approximately 50%. Second-line treatments, including hypomethylating agents (HMAs),...
6.
Pigneux A, Bene M, Guardiola P, Recher C, Hamel J, Sauvezie M, et al.
J Clin Oncol
. 2017 Jan;
35(4):387-393.
PMID: 28129526
Purpose Elderly patients with acute myeloid leukemia (AML) have a poor prognosis, and innovative maintenance therapy could improve their outcomes. Androgens, used in the treatment of aplastic anemia, have been...
7.
Greenberg P, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F, et al.
Blood
. 2016 Aug;
128(16):2096-2097.
PMID: 27535995
No abstract available.
8.
Pfeilstocker M, Tuechler H, Sanz G, Schanz J, Garcia-Manero G, Sole F, et al.
Blood
. 2016 Jun;
128(7):902-10.
PMID: 27335276
In myelodysplastic syndromes (MDSs), the evolution of risk for disease progression or death has not been systematically investigated despite being crucial for correct interpretation of prognostic risk scores. In a...
9.
Thepot S, Ben Abdelali R, Chevret S, Renneville A, Beyne-Rauzy O, Prebet T, et al.
Haematologica
. 2016 May;
101(8):918-25.
PMID: 27229713
The efficacy of azacitidine in patients with anemia and with lower-risk myelodysplastic syndromes, if relapsing after or resistant to erythropoietic stimulating agents, and the benefit of combining these agents to...
10.
Kosmider O, Passet M, Santini V, Platzbecker U, Andrieu V, Zini G, et al.
Haematologica
. 2016 Apr;
101(7):e280-3.
PMID: 27056923
No abstract available.